Controversy is in full swing over Madopar, a Parkinson's disease drug that withdrew from the Korean market early this year due to profitability issues. Patients want Madopar again, saying that the only remaining generic drug after Madopar was withdrawn has severe side effects. Furthermore, it raises the question of calculating the drug price of the original drug.

First of all, the government extended the grace period for Madopar's insurance benefit deletion from July 31st to December 31st. During this period, benefits can be applied even if Madopar is prescribed in stock. However, extending the grace period is only a short-term solution. After December 31st, it is clear that patients' dissatisfaction wi